Pharmaceutical Commerce - March 2021

A well-oiled, data-driven hub program is critical for stakeholders in supporting patients—and clearing a successful path for specialty therapies

Catchphrase or not, the patient journey is seemingly more complex than ever these days—upping the ante for new strategies in specialty-care support

2020 was a difficult year for many patients, but new data may signal a brighter future ahead

A conversation with Cathy Traz, global advocacy head at Bristol Myers Squibb

Non-commercial pharmacies can be secret weapons for intake and adherence

Their promise is prompting pharma leaders to give their hub/PAP CRM platforms a closer look

The key trends and considerations for specialty providers navigating a changing policy landscape

More leverage for community-based pharmacies and rules changes for drug-pricing reporting

Case study on closing the gap between new specialty drugs and specialty pharmacies